Company intelligence

PROK

ProKidney Corp. · NASDAQ · Healthcare

Price$1.64+2.40% · +$0.04

Market cap550.92MEquity value

P / E-3.1Trailing ratio

Volume862.35KLatest session

Market data

PROK price chart

TradingView

Related signals

1 min delayed

Browse public PROK signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PROKJul 9, 2025+39.41% since signal

ProKidney: What's Happening With PROK Stock?

PROK's Phase 2 trial results show significant kidney function improvement. Stock surged 500% post-announcement but remains 70% below 2023 highs. Robust cash balance of $358 million, with low debt levels. Risks include Phase 3 trial uncertainty and reliance on a single therapy. Analysts price targets average around $4, indicating current fair valuation.

View signal analysis

PROKJul 8, 2025+624.90% since signal

Why Is Penny Stock ProKidney Trading Higher On Tuesday?

ProKidney reported positive Phase 2 trial results for rilparencel in CKD patients. Rilparencel showed a 78% improvement in eGFR decline in Group 1. FDA Type B meeting scheduled for accelerated approval strategy confirmation. PROK stock surged 56.6% during premarket trading on positive news. No serious adverse events reported in the trial participants.

View signal analysis

Research